T2D: once-weekly semaglutide reduces HbA1c and body weight

  • Capehorn M & al.
  • Diabetes Ther
  • 19 Mar 2020

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with type 2 diabetes (T2D), once-weekly semaglutide 0.5 mg and 1.0 mg significantly improved glycated haemoglobin (HbA1c) level and body weight, with a similar tolerability profile, regardless of whether they receive background metformin (MET) or MET plus sulphonylurea (SU).

Why this matters

  • Findings support health care professionals in providing optimal care with glucagon-like peptide-1 receptor agonists (GLP-1RAs) on the basis of their background oral antidiabetic drugs (OADs) in patients with T2D.

Study design

  • A post hoc analysis of data from the SUSTAIN 2, 3, 4 and 10 trials included 3411 patients with T2D (3410 in the safety analysis).
  • Change in HbA1c level and body weight at the end of treatment visit (at 30 weeks for SUSTAIN 4 and 10 and at 56 weeks for SUSTAIN 2 and 3) and rates of hypoglycaemia and adverse events (AEs) were evaluated.
  • Funding: Novo Nordisk A/S.

Key results

  • Across 4 trials:
    • Semaglutide significantly reduced HbA1c (estimated treatment difference [ETD], −0.32 to −0.79%-points for 0.5 mg, and −0.38 to −1.07%-points for 1.0 mg vs comparators; P<.01 in patients who received both met and plus su.>
    • Semaglutide was associated with a significant reduction in body weight (ETD, −2.35 to −4.72 kg for 0.5 mg, and −2.96 to −6.76 kg for 1.0 mg vs comparators; P<.0001 irrespective of the background oad therapy.>
    • Hypoglycaemic events were more frequent in patients who received background MET plus SU vs those who received MET alone, regardless of whether they received semaglutide or a comparator.
    • Rate of AEs leading to premature treatment discontinuations in patients treated with semaglutide were consistent irrespective of the background OAD therapy.

Limitations

  • Post hoc analysis.